ArticlePloS one2025
Fatigue in Post-COVID-Condition is accompanied by hypoperfusion of right-occipital areas.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurological impairment in long COVID: implications for neurodegenerative disease.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeA proportion of individuals recovering from COVID-19 continue to experience persistent symptoms, including fatigue and cognitive difficulties - a syndrome commonly referred to as Post-COVID condition (PCC), which affects an estimated 2-10% of cases. In this study, we evaluated cerebral blood flow (CBF) to better understand the pathophysiological mechanisms underlying PCC. MATERIALS AND
methodsIn this prospective, monocentric study, we analyzed clinical and cerebral blood flow (CBF) data from a cohort of 55 patients who met the WHO diagnostic criteria for Post-COVID condition (PCC) and underwent MRI approximately 11 months after a positive PCR test for SARS-CoV-2. These PCC patients were compared to a matched control group of 36 individuals who had contracted COVID-19 but did not develop PCC. CBF was assessed using arterial spin labeling (ASL), a promising non-invasive technique that provides high spatial resolution for quantifying cerebral blood flow. Additionally, we examined changes in gray matter volume and atrophy using FreeSurfer-based cortical morphometry. We further explored the relationship between regional CBF alterations and clinical symptoms, including cognitive and olfactory function, as well as fatigue.
resultsIn our cohort, 59% of PCC patients could not return to their previous level of independence or employment due to symptoms, and 81% reported fatigue on the WEIMuS questionnaire. Conventional MRI showed no evidence of cortical atrophy. While no significant differences in regional CBF emerged after FDR correction, a more explorative threshold (p < 0.005) revealed reduced CBF in the right angular and middle occipital gyri in PCC patients. Fatigue, as assessed by the WEIMuS, was significantly correlated with reduced CBF in the right occipital regions, particularly for physical fatigue, but no associations were found with cognitive or olfactory performance.
conclusionIn PCC patients, fatigue was associated with reduced perfusion in right-sided occipital regions, suggesting a potential pathophysiological basis for this symptom. These findings may also provide an imaging biomarker to aid in the diagnosis of PCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.